Novo Nordisk fired a direct shot at Eli Lilly this week, releasing data from an indirect trial comparison that claims its oral semaglutide 25 mg pill delivered greater weight loss and fewer side-effect dropouts than Lilly’s orforglipron 36 mg. The analysis, called ORION, arrives just one day after the FDA approved Lilly’s oral weight-loss pill, sharpening the competitive stakes in a market where both companies are betting that pills, not injections, will define the next phase of obesity treatment.
What the ORION Comparison Found
The ORION analysis is a population-adjusted indirect treatment comparison, meaning it did not pit the two drugs against each other in a single trial. Instead, Novo Nordisk matched patient populations across two separate studies: its own OASIS 4 trial of oral semaglutide 25 mg and Lilly’s ATTAIN-1 trial of orforglipron 36 mg. Both trials enrolled adults with overweight or obesity who did not have diabetes.
According to Novo’s summary of the ORION results, the Wegovy pill produced greater mean weight loss than orforglipron at the 36 mg dose and was associated with lower odds of stopping treatment because of side effects. The company says the comparison used standard methods to adjust for differences in baseline characteristics between the OASIS 4 and ATTAIN-1 populations. Novo plans to share a full readout of the analysis at the upcoming obesity meeting, positioning the findings as evidence that its oral GLP-1 could be the more potent and tolerable option.
The Trials Behind the Numbers
OASIS 4, registered as NCT05564117, ran for roughly 64 weeks and tested oral semaglutide in adults whose body weight exceeded the healthy range. The study, sponsored by Novo Nordisk, was published in the New England Journal of Medicine and reported substantial average weight loss alongside a safety profile dominated by gastrointestinal complaints typical of GLP-1 agonists. Novo had already been promoting the 25 mg formulation as a “Wegovy in a pill,” pointing to both the magnitude of weight reduction and what it described as favorable tolerability data at higher doses.
On Lilly’s side, ATTAIN-1, listed under NCT05869903, evaluated orforglipron across multiple dose levels, including the 36 mg arm that serves as ORION’s comparator. Like OASIS 4, ATTAIN-1 enrolled adults with obesity or overweight who did not have diabetes and followed them long enough to capture both peak weight loss and durability over time. The New England Journal of Medicine publication on orforglipron outcomes detailed dose-dependent reductions in body weight, again with gastrointestinal side effects as the main tolerability concern and a measurable fraction of participants discontinuing because of adverse events.
Together, these two peer-reviewed trials provide the raw clinical evidence that ORION uses to construct its cross-study comparison. The indirect analysis itself, however, has so far only been described in press materials rather than a journal article, meaning outside statisticians have not yet had the chance to fully scrutinize its assumptions or reproduce its findings.
Why Indirect Comparisons Deserve Skepticism
The critical distinction is that ORION is not a head-to-head trial. Population-adjusted indirect comparisons are a familiar tool in pharmaceutical development and health technology assessment, especially when payers or regulators need to weigh drugs that have never been directly compared. But they come with well-known limitations. Differences in trial design, background lifestyle counseling, titration schedules, and definitions of endpoints can all influence apparent treatment effects, even after statistical adjustment.
Independent commentators have already urged caution when extrapolating across obesity trials. A clinical analysis of the OASIS 4 data, for example, underscored that cross-trial comparisons can be informative but rarely definitive, particularly when patient populations differ in subtle ways such as prior weight-loss attempts or comorbid conditions. Those caveats apply just as strongly here: ORION is an industry-sponsored exercise designed and executed by Novo Nordisk, which selected the input studies and the modeling approach.
That does not mean the results are meaningless. If the analysis is robust, a lower rate of discontinuation due to side effects could matter in practice, because real-world weight loss depends heavily on staying on therapy. Nausea, vomiting and diarrhea are common enough with GLP-1 drugs that many patients stop early, forfeiting much of the potential benefit. A pill that people can tolerate for a full year or more may deliver better outcomes even if the nominal percentage weight loss at 36 or 52 weeks appears similar on paper.
Lilly’s Approval Changes the Calculus
The timing of Novo’s announcement is closely tied to Lilly’s regulatory milestone. The recent FDA decision to approve Lilly’s oral weight-loss pill for obesity instantly gave the company a commercial foothold in the oral GLP-1 segment. That first-mover status matters in a market where brand familiarity, insurance coverage decisions and prescriber habits can lock in advantages that last for years.
Novo, for its part, already sells an injectable version of semaglutide for obesity and has been building awareness of its oral formulation in other indications. But a once-daily tablet specifically labeled for weight management is a different proposition. According to recent reporting, many people starting on oral semaglutide are new to GLP-1 therapy altogether, suggesting that pills are expanding the pool of treated patients rather than merely cannibalizing injections.
That shift could reshape the economics of obesity care. A far larger segment of the population is willing to take a daily tablet than to self-inject weekly, especially for a chronic condition that may require years of treatment. If oral GLP-1s prove both effective and tolerable, they could move from specialist obesity clinics into primary care, where physicians manage most patients with overweight or obesity. In that scenario, even modest differences in efficacy or side-effect profiles between brands could sway prescribing patterns at scale.
What Actually Matters for Patients
For individuals considering treatment, the corporate rivalry is secondary to two questions: how much weight they can expect to lose and whether they can remain on the drug long enough to maintain that loss. Both oral semaglutide and orforglipron have demonstrated double-digit percentage reductions in body weight in clinical trials among people without diabetes, when combined with lifestyle counseling. Those averages, however, conceal wide variation. Some participants lose far more than the mean, while others see only modest changes even with good adherence.
Side effects are equally personal. The same nausea that one person finds tolerable may be debilitating to another. Trial data suggest that gastrointestinal symptoms are most pronounced during dose escalation and may subside over time, but a significant minority of patients discontinue because of them. If ORION’s finding of fewer discontinuations with semaglutide holds up under independent review, that could tilt some clinicians toward Novo’s pill for patients who are especially sensitive to side effects. Conversely, if direct comparisons later show similar tolerability, factors like insurance coverage, pharmacy access and patient preference may matter more than marginal differences in efficacy.
Cost and availability will also shape real-world choices. Even with insurance, out-of-pocket expenses for obesity medications can be substantial, and coverage policies vary widely. Some payers may favor one product over another through formulary placement or prior-authorization rules, effectively steering patients toward the drug with the better negotiated price. Until both pills are widely available and reimbursement patterns stabilize, many patients may simply take whichever option their insurer is willing to cover.
Looking Ahead
The ORION comparison is best viewed as an opening salvo in what is likely to become a prolonged contest over oral obesity therapies. Novo Nordisk has used its media channels to frame oral semaglutide as the more effective and tolerable choice, while Lilly can point to its FDA approval and its own robust trial data to argue that orforglipron is highly competitive. Ultimately, definitive answers about relative performance will require randomized head-to-head trials that enroll similar patients, follow them for at least a year and use harmonized endpoints for weight loss, safety and quality of life.
Until those data arrive, clinicians and patients will have to navigate an imperfect evidence base, balancing promising but indirect comparisons against the concrete details of individual circumstances. For now, the emergence of multiple potent oral options is itself a notable shift. After decades in which obesity pharmacotherapy was defined by modest efficacy and frequent safety setbacks, the field is entering a phase where competition revolves around how much weight can be lost, how long it can be kept off and how comfortable patients feel along the way, questions that matter far more than which company can claim an early statistical edge.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
